Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emergent BioSolutions Inc. (NYSE: EBS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange‑listed pharmaceutical preparation manufacturing company, Emergent submits annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its operations, financial condition and material events.
In its recent Form 8‑K filings, Emergent has reported topics such as quarterly financial and operating results, voluntary prepayment under a term loan facility, contract modifications and options for medical countermeasures, regulatory approvals for manufacturing changes, and changes in board membership. These current reports often incorporate press releases and presentation materials by reference, giving additional detail on product revenues, segment performance and government contract activity.
Filings also confirm that Emergent’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol EBS. Disclosures identify its reportable segments, including Commercial Products and MCM Products, and describe how Services and contracts and grants revenues are presented. Other events filings outline contract modifications with agencies such as the Administration for Strategic Preparedness and Response and BARDA for products including ACAM2000®, CYFENDUS™, BioThrax® and BAT®.
On Stock Titan, investors can review these SEC documents alongside AI‑generated summaries that highlight key points from lengthy filings. Real‑time updates from EDGAR surface new 10‑K and 10‑Q reports as they are filed, while Form 8‑K items flag significant developments in financing, contracts, regulatory approvals and governance. Users can also track how Emergent describes its medical countermeasures portfolio, naloxone products and segment structure over time through its official regulatory language.